Previous Close | 48.01 |
Open | 47.27 |
Bid | 47.56 x 38700 |
Ask | 47.65 x 105300 |
Day's Range | 47.35 - 47.75 |
52 Week Range | 43.53 - 71.14 |
Volume | |
Avg. Volume | 552,184 |
Market Cap | 13.948B |
Beta (5Y Monthly) | 0.94 |
PE Ratio (TTM) | 15.89 |
EPS (TTM) | 3.00 |
Earnings Date | Aug 02, 2022 |
Forward Dividend & Yield | 1.35 (2.73%) |
Ex-Dividend Date | May 13, 2022 |
1y Target Est | 64.66 |
Subscribe to Yahoo Finance Plus to view Fair Value for FME.DE
The U.S. Supreme Court on Tuesday rejected dialysis provider DaVita Inc's claims that an Ohio hospital's employee health plan discriminates against patients with end-stage kidney disease by reimbursing them at low rates in hopes they would switch to Medicare. In a 7-2 decision https://fingfx.thomsonreuters.com/gfx/legaldocs/byvrjaqorve/06212022davita.pdf authored by conservative Justice Brett Kavanaugh, the court ruled that Marietta Memorial Hospital's employee health plan did not violate federal law by limiting benefits for outpatient dialysis because it did so without regard to whether patients had end-stage renal disease.
Fresenius Medical (FMS) continues to gain traction through its broad dialysis product and service portfolio. Intense competition is a woe.
HONG KONG, May 12, 2022--Fresenius Medical Care, the world’s leading provider of products and services for individuals with renal diseases, today announced its global ‘United in Care’ campaign that celebrates the diversity, unity and positive impact of its nurses and clinical teams across Asia Pacific, Europe, the Middle East and Africa, North America and Latin America.